Abstract
Introduction. Despite of the potential of TMS as an FDA-approved depression-treatment (George et al., 2010), not all patients respond (McClintock et al., 2017). Recently developed TMS/fMRI setups allow for precise investigations on the TMS mechanism of action. We recently demonstrated that TMS over M1 leads to linear BOLD-increase depending on stimulation intensity (Navarro de Lara et al., 2017). However, it remains unclear if sensitivity profiles observed in M1 also apply for DLPFC, as an important target in depression therapy. Using an improved sham condition and in-scanner neuronavigation with online tracking we investigated if DLPFC dose-response profiles are comparable to those of the motor cortex.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
